Fig. 2

Quality assessment of the assay. (a) The 384-well plate-based model system with cancer cell monocultures analyzed using FMCA. (b-c) Viability of HCT116-GFP (b) and A549-NLR (c) cells, cultured as monocultures and treated with the validation drug panel at 1, 10, and 30 µM for 72 h, measured by FMCA and by image-based quantification of fluorescence. Correlation between the two assays determined by calculating Lin’s Concordance Correlation Coefficient (CCC). One representative experiment shown with data presented as means from three technical replicates. (d-e) Dose-response curves for the example drugs thioguanine and ruxolitinib. Viability measured in HCT116-GFP (d) and A549-NLR (e) with dual readouts after 72 h treatment. Data shown as mean ± SEM from three independent experiments. (f-h) Correlation between Bliss scores obtained with immune cells from three different donors (f-g) and between independent experiments performed with the same donor (h) determined by calculating CCC. Bliss Scores were calculated for HCT116-GFP after treatment with the validation drug panel at 1, 10, and 30 µM for 72 h